Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
30 pending office actions • 15 clients • 30 examiners • 29 art units • 0 of 30 (0%) have an AI response strategy ready • 31 patents granted in the last 365 days
Adams & Reese LH focuses on Biotechnology & Pharmaceuticals and has 29 pending office actions. Its record includes 1805 career applications, giving the reported metrics a substantial prosecution base.
The resolved allowance rate is 74.7%, and applications reaching allowance have averaged 3.39 office actions. The figures indicate a sizeable practice with a resolved outcome record that merits matter-level review, alongside examination histories commonly involving multiple office-action responses.
Based on the USPTO statutory response window for each pending office action. 11 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 11 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (10%) |
| §103 only | 9 (30%) |
| §112 only | 2 (7%) |
| Double-patenting + other | 3 (10%) |
| Multi-statute (no §101) | 13 (43%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RHOADES, DEREK JAMES | 1 | 72.3% | +16.5% |
| CHOI, PETER H | 1 | 26.3% | +18.5% |
| AGUIRRE, AMANDA L | 1 | 77.3% | +15.7% |
| JUNG, JONATHAN Y | 1 | 72.7% | +16.9% |
| FUBARA, BLESSING M | 1 | 62.2% | +34.1% |
| TRA, TUYEN Q | 1 | 85.6% | +9.2% |
| GORDON, BRIAN R | 1 | 65.3% | +19.0% |
| TACDIRAN, ANDRE GEE | 1 | 80.3% | +19.7% |
| BLUMEL, BENJAMIN P | 1 | 70.7% | +30.6% |
| SIDDIQUEE, MUHAMMAD S | 1 | 78.2% | +19.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18720864 | Radio Access Network Control System | TACDIRAN, ANDRE GEE | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17916702 | Use of Mitochondria-Targeted Antioxidants to Treat Severe Inflammatory Conditions | JOHNSON, CHRISTOPHER LINDSAY | 45d overdue |
| 18008323 | Ferromagnetic Metal-Ferrite Composites for High Frequency Inductor Applications | EDMONDSON, LYNNE RENEE | 37d overdue |
| 18038338 | Bioactive complexes | PACKARD, BENJAMIN J | 35d overdue |
| 18031486 | Engineered Cells for Increased Collagen Production | MARVICH, MARIA | 9d overdue |
| 17523861 | Method for Direct Synthesis of Nanomaterials by Heating of Bulk Sources | MCCLAIN, STARFARI TESHAWN | 3d overdue |
| 18578066 | Serotonin 5-HT2A, 5-HT2B, and 5-HT2C Receptor Inverse Agonists | HASTINGS, ALISON AZAR | 39d |
| 19630016 | CRYSTALLINE FORMS OF ANTIOXIDANT COMPOUND | RHOADES, DEREK JAMES | — |
| 19112461 | Computer Vision Based Assessment of Infant Face and Body Symmetry | CHOI, PETER H | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19630016 | CRYSTALLINE FORMS OF ANTIOXIDANT COMPOUND | RHOADES, DEREK JAMES | — |
| 19112461 | Computer Vision Based Assessment of Infant Face and Body Symmetry | CHOI, PETER H | — |
| 19048532 | Anti-Amyloidogenic Curcumin Analogues | AGUIRRE, AMANDA L | — |
| 18962393 | Metalenses for Use in Night-Vision Technology | JUNG, JONATHAN Y | — |
| 18825450 | Biodegradable Implant for Sustained Trans-Nasal Delivery of Therapeutic Agents to the Brain | FUBARA, BLESSING M | — |
| 18783022 | Single Cell Isolation and Processing System With Reversible Well Shape | GORDON, BRIAN R | — |
| 18720864 | Radio Access Network Control System | TACDIRAN, ANDRE GEE | — |
| 18643793 | MOLECULAR VACCINES FOR INFECTIOUS DISEASE | BLUMEL, BENJAMIN P | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Northeastern University | 15 |
| CureVac | 2 |
| Mitotech Ltd. | 1 |
| Mcphs University | 1 |
| Mass General Brigham | 1 |
| Agilent | 1 |
| Stahl International B.V. | 1 |
| Ceradis Patent B.V. | 1 |
| Herlev Hospital | 1 |
| Mitotech | 1 |
| Ixaka | 1 |
| Firebrand Therapeutics, Inc. | 1 |
| aratinga.bio | 1 |
| INSTITUT QUIMIC DE SARRIA CETS FUNDAClÓ PRIVADA | 1 |
| Immudex ApS | 1 |
| Art Unit | Apps |
|---|---|
| 1692 | 1 |
| 3681 | 1 |
| 2871 | 1 |
| 1613 | 1 |
| 2872 | 1 |
| 1798 | 1 |
| 2415 | 1 |
| 1671 | 1 |
| 1723 | 1 |
| 2648 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19630016 | CRYSTALLINE FORMS OF ANTIOXIDANT COMPOUND | Mitotech Ltd. | RHOADES, DEREK JAMES | 1692 | §102§103§112Other | Non-Final OA | — | Pending | Mar 26, 2026 |
| 19112461 | Computer Vision Based Assessment of Infant Face and Body Symmetry | Northeastern University | CHOI, PETER H | 3681 | §101§103§112 | Non-Final OA | — | Pending | Mar 17, 2025 |
| 19048532 | Anti-Amyloidogenic Curcumin Analogues | Mcphs University | AGUIRRE, AMANDA L | §102§103§112 | Non-Final OA | — | Pending | Feb 07, 2025 | |
| 18962393 | Metalenses for Use in Night-Vision Technology | Northeastern University | JUNG, JONATHAN Y | 2871 | §103§112 | Non-Final OA | — | Pending | Nov 27, 2024 |
| 18825450 | Biodegradable Implant for Sustained Trans-Nasal Delivery of Therapeutic Agents to the Brain | Massachusetts Eye And Ear Infirmary | FUBARA, BLESSING M | 1613 | §102§103DP | Non-Final OA | — | Pending | Sep 05, 2024 |
| 18833512 | Self-Administered Adaptive Vision Screening Test Using Angular Indication | Northeastern University | TRA, TUYEN Q | 2872 | §102§103§112 | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18783022 | Single Cell Isolation and Processing System With Reversible Well Shape | Northeastern University | GORDON, BRIAN R | 1798 | §102§103§112 | Non-Final OA | — | Pending | Jul 24, 2024 |
| 18720864 | Radio Access Network Control System | Northeastern University | TACDIRAN, ANDRE GEE | 2415 | §103 | Final Rejection | — | Pending | Jun 17, 2024 |
| 18643793 | MOLECULAR VACCINES FOR INFECTIOUS DISEASE | Agilent Technologies, Inc. | BLUMEL, BENJAMIN P | 1671 | §112 | Final Rejection | — | Pending | Apr 23, 2024 |
| 18700384 | Solid State Energy Storage Devices Monolithically Printed from Dispersions | Northeastern University | SIDDIQUEE, MUHAMMAD S | 1723 | §103 | Non-Final OA | — | Pending | Apr 11, 2024 |
| 18620310 | Methods for Real-Time Wideband RF Waveform and Emission Classification | Northeastern University | TALUKDER, MD K | 2648 | §103 | Final Rejection | — | Pending | Mar 28, 2024 |
| 18689955 | Thermoformable Boron-Based Ceramic Material and Use in Thermal Management | Northeastern University | KIM, YUNJU | 1742 | §103 | Final Rejection | 46d | Pending | Mar 07, 2024 |
| 18578066 | Serotonin 5-HT2A, 5-HT2B, and 5-HT2C Receptor Inverse Agonists | Northeastern University | HASTINGS, ALISON AZAR | 1627 | §102§103§112Other | Final Rejection | 39d | Pending | Jan 10, 2024 |
| 18542532 | Ultrasensitive Label-Free Profiling of Glycans Released from Single Cells | Northeastern University | ALABI, OYELEYE A | 1651 | §101§103 | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18540481 | Method for High Purity High Throughput Isolation of Extracellular Vesicles Using Size Exclusion Chromatography | Northeastern University | NORRIS, CLAIRE A | 1779 | §103 | Final Rejection | 33d | Pending | Dec 14, 2023 |
| 18565980 | A MACHINE FOR EMBOSSING LEATHER | Stahl International B.V. | ZIMMERMAN, JOSHUA D | 2853 | §102§103 | Final Rejection | — | Pending | Nov 30, 2023 |
| 18287539 | Site-Specific Modification of Glycoproteins Through Transglutaminase-Mediated Conjugation | Northeastern University | STONEBRAKER, ALYSSA RAE | 1642 | §103§112 | Non-Final OA | — | Pending | Oct 19, 2023 |
| 18038338 | Bioactive complexes | Ceradis Patent B.V. | PACKARD, BENJAMIN J | 1612 | §102§103 | Non-Final OA | 35d overdue | Pending | May 23, 2023 |
| 18304028 | General Detection and Isolation of Specific Cells by Binding of Labeled Molecules | Herlev Hospital | FLINDERS, JEREMY C | 1684 | §103DP | Non-Final OA | — | Pending | Apr 20, 2023 |
| 18031486 | Engineered Cells for Increased Collagen Production | Northeastern University | MARVICH, MARIA | 1634 | §103§112 | Non-Final OA | 9d overdue | Pending | Apr 12, 2023 |
| 18008323 | Ferromagnetic Metal-Ferrite Composites for High Frequency Inductor Applications | Northeastern University | EDMONDSON, LYNNE RENEE | 1734 | §103§112 | Final Rejection | 37d overdue | Pending | Dec 05, 2022 |
| 17916702 | Use of Mitochondria-Targeted Antioxidants to Treat Severe Inflammatory Conditions | Mitotech S.A. | JOHNSON, CHRISTOPHER LINDSAY | 1691 | §102§112 | Final Rejection | 45d overdue | Pending | Oct 03, 2022 |
| 17777106 | Polymer-Encapsulated Viral Vectors for In Vivo Genetic Therapy | Ixaka France | MATALKAH, FATIMAH KHALAF | 1638 | §103 | Non-Final OA | — | Pending | May 16, 2022 |
| 17642789 | Inhibitor of metadherin expression | Firebrand Therapeutics, Inc. | SHIN, DANA H | 1635 | §112 | Final Rejection | — | Pending | Mar 14, 2022 |
| 17523861 | Method for Direct Synthesis of Nanomaterials by Heating of Bulk Sources | Northeastern University | MCCLAIN, STARFARI TESHAWN | 1736 | §102§103 | Non-Final OA | 3d overdue | Pending | Nov 10, 2021 |
| 17263258 | CANCER VACCINES FOR UTERINE CANCER | Curevac Netherlands B.V. | VAN DRUFF, SYDNEY | 1643 | §103 | Final Rejection | 19d | Pending | Jan 26, 2021 |
| 17261997 | METHOD OF PREPARING SUBJECT-SPECIFIC IMMUNOGENIC COMPOSITIONS BASED ON A NEO OPEN-READING-FRAME PEPTIDE DATABASE | Curevac Netherlands B.V. | BAUSCH, SARAE L | 1699 | §101§112 | Non-Final OA | — | Pending | Jan 21, 2021 |
| 16962686 | Polymer-Encapsulated Viral Vectors for Genetic Therapy | Aratinga.Bio Tnp | LANKFORD JR, LEON B | 1657 | §103 | Non-Final OA | — | Pending | Jul 16, 2020 |
| 15908112 | MODIFIED POLY (BETA-AMINO ESTER)S FOR DRUG DELIVERY | Institut Químic de Sarrià | POPA, ILEANA | 1633 | §103 | Non-Final OA | 8d | Pending | Feb 28, 2018 |
| 15316584 | Determining Antigen Recognition through Barcoding of MHC Multimers | Immudex Aps | DIBRINO, MARIANNE | 1641 | §102§103§112DPOther | Final Rejection | 73d overdue | Pending | Dec 06, 2016 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial74.7% of resolved applications prosecuted by Adams & Reese Lh were allowed, across 1,805 applications in USPTO records.
3.39 office actions per allowed application on average.
30 pending office actions as of October 2026, for 15 clients, before 30 examiners in 29 art units.
